A Phase I Trial of the Combination of the PARP Inhibitor ABT-888 With Intraperitoneal Floxuridine (FUDR) in Epithelial Ovarian, Primary Peritoneal and Fallopian Tube Cancers
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 06 Jun 2019
At a glance
- Drugs Veliparib (Primary) ; Veliparib (Primary) ; Floxuridine
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Biomarker; Pharmacogenomic
- 28 Mar 2018 Status changed from recruiting to active, no longer recruiting.
- 19 Jan 2018 Planned primary completion date changed from 30 Jun 2017 to 16 Jan 2019.
- 17 Oct 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Jun 2017.